{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "exchange": "FRA", "shortName": "AVALO THERAPEUT.  DL-,001", "longName": "Avalo Therapeutics, Inc.", "messageBoardId": "finmb_145313032", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -1.8018, "regularMarketPrice": 2.18, "marketCap": 30515422, "priceToBook": -1.8841834, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Cerecor Inc.", "nameChangeDate": "2023-05-11", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1524117600000, "priceHint": 4, "regularMarketChange": -0.03999996, "regularMarketTime": 1683892036, "regularMarketDayHigh": 2.18, "regularMarketDayRange": "2.16 - 2.18", "regularMarketDayLow": 2.16, "regularMarketVolume": 4900, "regularMarketPreviousClose": 2.22, "bid": 0.0, "ask": 0.0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 2.16, "averageDailyVolume3Month": 167, "averageDailyVolume10Day": 490, "fiftyTwoWeekLowChange": 0.72, "fiftyTwoWeekLowChangePercent": 0.49315068, "fiftyTwoWeekRange": "1.46 - 6.95", "fiftyTwoWeekHighChange": -4.7699995, "fiftyTwoWeekHighChangePercent": -0.68633085, "fiftyTwoWeekLow": 1.46, "fiftyTwoWeekHigh": 6.95, "earningsTimestamp": 1683230496, "earningsTimestampStart": 1690979400, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.88, "sharesOutstanding": 13200500, "bookValue": -1.157, "fiftyDayAverage": 2.264, "fiftyDayAverageChange": -0.08399987, "fiftyDayAverageChangePercent": -0.03710242, "twoHundredDayAverage": 3.98606, "twoHundredDayAverageChange": -1.8060598, "twoHundredDayAverageChangePercent": -0.453094, "symbol": "C6K.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "540 Gaither Road", "address2": "Suite 400", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "410 522 8707", "website": "https://www.avalotx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Dr. Garry A. Neil M.D.", "age": 68, "title": "Chairman, Pres & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 601900, "fmt": "601.9k", "longFmt": "601,900"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher Ryan Sullivan", "age": 38, "title": "CFO & Head of Investor relations", "yearBorn": 1984, "fiscalYear": 2022, "totalPay": {"raw": 466935, "fmt": "466.94k", "longFmt": "466,935"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Solomon H. Snyder M.D.", "age": 83, "title": "Founder and Chairman of Scientific Advisory Board", "yearBorn": 1939, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Barbara S. Slusher Ph.D.", "age": 57, "title": "Founder and Member of Scientific Advisory Board", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lisa  Hegg Ph.D.", "title": "Sr. VP of Program Management, Corp. Infrastructure & Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Colleen  Matkowski", "title": "Sr. VP of Global Regulatory Affairs & Quality Assurance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dino C. Miano Ph.D.", "title": "Sr. VP of CMC & Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}